Reference | No. of patients | Technique | Sensitivity, % (no. of patients)* | Specificity, % (no. of patients)* |
---|---|---|---|---|
Braun et al. (236) | 32 | MET PET | 87 (26/30) | 75 (3/4) |
Pirotte et al. (4) | 32 | MET PET | 100 (61/61) | 100 (9/9) |
Kracht et al. (237) | 30 | MET PET | 87 (87/100) | 89 (16/18) |
Pauleit et al. (5) | 31 | FET PET | 93† | 94† |
MRI‡ | 96 | 53 |
↵* As determined from analyzed lesions or biopsies.
↵† Total of 52 samples, 26 positive for tumor tissue.
↵‡ Combined analysis of nonenhanced T1-weighted sequences, Gd-enhanced sequences, and FLAIR sequences.
Sensitivity and specificity were calculated from fitted receiver operating characteristic curve.